Behcet's disease in children: single-center experience

被引:17
作者
Cirkinoglu, Murat Soner [1 ]
Demir, Selcan [2 ]
Bilginer, Yelda [2 ]
Ozen, Seza [2 ]
机构
[1] Hacettepe Univ, Tip Fak, Cocuk Sagligi & Hastaliklari Anabilim Dali, Ankara, Turkey
[2] Hacettepe Univ, Tip Fak, Cocuk Sagligi & Hastaliklari Anabilim Dali, Cocuk Romatoloji Bilim Dali, Ankara, Turkey
来源
TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS | 2019年 / 54卷 / 03期
关键词
Behcet's syndrome; HLA-B51; pediatrics; CLINICAL-FEATURES; MANAGEMENT;
D O I
10.14744/TurkPediatriArs.2019.15045
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: In this study, it was aimed to summarize the demographics, and clinical and laboratory findings of children who were diagnosed as having Behcet's disease, and also to determine the efficacy, duration, and adverse effects of the treatments. Material and Methods: The records of 34 patients who were diagnosed according to the International Behcet Study Group criteria between 1980 and 2013 in the Department of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, were retrospectively reviewed and all demographic and clinical features were recorded. In the light of these data, the sex and age distribution, clinical and laboratory findings, most commonly preferred treatment approaches, efficacy of treatments, and adverse effects during treatment were analyzed. Results: Of the 34 children with Behcet's disease, 18 (53%) were male and 16 (47%) were female, and the mean age was 11.18 +/- 3.34 years. There was no significant difference in age distribution of the male and female patients (p<0.05). In 97% (n=33) of the patients, the first symptom was recurrent oral aphthae. In order of frequency, the other mucocutaneous findings were pseudofoliculitis and pustular lesions (82%), genital ulcers (62%), and pathergy positivity (50%). System involvements in order of frequency were as follows: joint findings (38%), ocular findings (35%), vascular involvement (32%), neurologic involvement (18%), gastrointestinal involvement (5.8%), and pulmonary involvement (5.8%). Colchicine was the most commonly preferred drug (88%). Steroids were added to treatment in patients with skin involvement. Azathioprine was added in patients with uveitis. Anticoagulant therapy, cyclophosphamide, and anti-tumor necrosis factor-alpha were added in patients with vascular involvement. In patients with gastrointestinal system involvement, sulfasalazine was added to treatment. Diarrhea was the most common adverse effect in patients who used coichicine. In the patients who used steroid treatment, gastrointestinal symptoms such as unintentional weight gain, acne, and agitation were observed (17%). One patient who received interferon treatment had symptoms of depression and agitation. Conclusion: The aim of this study was to review the general characteristics of pediatric patients with Behcet's disease and to emphasize the importance of early diagnosis and correct treatment in terms of mortality and morbidity.
引用
收藏
页码:179 / 184
页数:6
相关论文
共 22 条
[11]   Demographic and clinical properties of juvenile-onset Behcet's disease: A controlled multicenter study [J].
Karincaoglu, Yelda ;
Borlu, Murat ;
Toker, Sernra Cikman ;
Akman, Ayse ;
Onder, Meltem ;
Gunasti, Suhan ;
Usta, Aysegul ;
Kandi, Basak ;
Durusoy, Cicek ;
Seyhan, Muammer ;
Utas, Serap ;
Saricaoglu, Hayriye ;
Ozden, Muge Guler ;
Uzun, Soner ;
Tursen, Umit ;
Cicek, Demet ;
Donmez, Levent ;
Alpsoy, Erkan .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (04) :579-584
[12]  
Kilian NC, 2017, EUR J RHEUMATOL, V4, P239, DOI 10.5152/eurjrheum.2017.17112
[13]   CLINICAL ANALYSIS OF 40 CASES OF CHILDHOOD-ONSET BEHCET-DISEASE [J].
KIM, DK ;
CHANG, SN ;
BANG, D ;
LEE, ES ;
LEE, S .
PEDIATRIC DERMATOLOGY, 1994, 11 (02) :95-101
[14]   Clinical features of Behcet's disease in children:: An international collaborative study of 86 cases [J].
Koné-Paut, I ;
Yurdakul, S ;
Bahabri, SA ;
Shafae, N ;
Ozen, S ;
Özdogan, H ;
Bernard, JL .
JOURNAL OF PEDIATRICS, 1998, 132 (04) :721-725
[15]   Consensus classification criteria for paediatric Behcet's disease from a prospective observational cohort: PEDBD [J].
Kone-Paut, Isabelle ;
Shahram, Fahrad ;
Darce-Bello, Martha ;
Cantarini, Luca ;
Cimaz, Rolando ;
Gattorno, Marco ;
Anton, Jordi ;
Hofer, Michael ;
Chkirate, Bouchra ;
Bouayed, Kenza ;
Tugal-Tutkun, Ilknur ;
Kuemmerle-Deschner, Jasmin ;
Agostini, Helene ;
Federici, Sylvia ;
Arnoux, Armelle ;
Piedvache, Celine ;
Ozen, Seza .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) :958-964
[16]  
Ozdal Pinar Cakar, 2002, Documenta Ophthalmologica, V105, P301
[17]   The spectrum of vasculitis in children [J].
Ozen, S .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (03) :411-425
[18]   Recent advances in childhood vasculitis [J].
Ozen, Seza ;
Acar-Ozen, Nazire Pinar .
CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (05) :530-534
[19]   The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease [J].
Sano, K ;
Yabuki, K ;
Imagawa, Y ;
Shiina, T ;
Mizuki, N ;
Ohno, S ;
Kulski, JK ;
Inoko, H .
TISSUE ANTIGENS, 2001, 58 (02) :77-82
[20]   A CONTROLLED TRIAL OF AZATHIOPRINE IN BEHCETS SYNDROME [J].
YAZICI, H ;
PAZARLI, H ;
BARNES, CG ;
TUZUN, Y ;
OZYAZGAN, Y ;
SILMAN, A ;
SERDAROGLU, S ;
OGUZ, V ;
YURDAKUL, S ;
LOVATT, GE ;
YAZICI, B ;
SOMANI, S ;
MUFTUOGLU, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (05) :281-285